Life Science Nation Newsletter  | December 21,  2017  |  Issue 245

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
Life Science Investor Mandates (Dec. 14  - Dec. 20)
Seeking Investment Opportunities in Healthcare, Automation/Robotics Companies and Relations to Healthcare
Invests in Therapeutics, Medical Devices, Diagnostic Imaging and Healthcare IT
Seeking Equity Investment and Licensing Opportunities in China and the US
Invests in Early-Stage Companies in the Biotech Therapeutics, Medical Technology and Devices, Diagnostics, and Healthcare IT Sectors
In This Issue
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Services
Click to see investors that are a fit for your product and stage of development

Click here if you are a service provider and want to see a list of funded life science companies that are a fit for you

Click here if you want to receive free, targeted early stage dealflow for your life science investment firm

Free Copy of LSN's Book

LSN Videos
By Chris Cummings, Senior Marketing Manager, LSN

Happy Holidays! With just under 3 weeks until the 4th annual RESI San Francisco, LSN is proud to announce this year's crop of innovative new life science companies participating in the RESI Innovation Challenge.

The RESI Innovation Challenge covers startups in therapeutics, medtech, diagnostics and healthcare IT companies from around the globe. All applicants are vetted based on not only the quality of the company's scientific work, but also the strength of the management team and how well-positioned the company is to receive investment...


MedTech Device

MedTech Diagnostic

Healthcare IT

By Lucy Parkinson, Director of Research, LSN

Major pharma firms are increasingly looking to startups to supply new assets for their pipelines, and LSN's research has found that many are interested in inking deals at the earliest stages of drug development. Going into 2017, we found that a plurality of pharma deals announced in the previous year concerned preclinical assets.

Due to RESI's focus on early stage life science companies, the vent has become known as a venue for top pharma firms to uncover new therapeutic opportunities. At RESI San Francisco, the panel on Big Pharma will provide an opportunity to hear straight from five experienced scouts on what they're looking for, how they make deals and what makes a pharma partnership work. 

Moderated by Chris Haskell, VP, Head of West Coast Innovation Center, Bayer Healthcare, the panelists are:
  • Kevin Lynch, Vice President, Search & Evaluation, AbbVie
  • Chris Sheldon, Head, Oncology Search & Evaluation, AstraZeneca
  • Lesley Stolz, Head, JLABS California, Johnson & Johnson Innovation
  • Chris DeRespino, Director Transactions, Amgen
By Cole Bunn, Senior Research Analyst, LSN

A large number of early stage biotechs are pursuing orphan disease indications. This trend is driven by the large number of rare diseases with either no current treatment options or severely inadequate therapies as well as the unique regulatory/development advantages available for these therapeutics. However, orphan drugs also face some unique challenges, such as clinical trial recruitment, pricing, and small market sizes. Recent developments in the space should make for an interesting year to come with the new FDA head, Dr. Scott Gottlieb, planning to eliminate the backlog of orphan drug designation requests and the halving of the orphan drug tax credit.

In the highly anticipated RESI @ JPM conference on January 9, 2018, a varied group of investors active in the orphan/rare disease space will discuss the financing and business development environment for startups working on developing drugs for orphan indications.

Moderated by Ken Kengatharan, General Partner, Atheneos Capital panelists include:
  • Gregory Fond, Business Development & Licensing (Rare Diseases), Sanofi
  • Ben Yerxa, CEO, Foundation Fighting Blindness
  • Jose Antonio Mesa, Life Sciences Director, Caixa Capital Risc
  • Basheer Zada, Business Development Manager, Brace Pharma Capital

Created & Produced by

QuickFire Challenge
I n honor of the Grand Opening of JLABS @ NYC, Johnson & Johnson Innovation has launched a QuickFire Challenge to award up to four new game-changing early-stage innovation companies with the use of a bench, workstation and access to the JLABS @ NYC community for one year.

This competition will award the person or team(s) who submits the best idea, technology, or solution in the following areas:
  • Consumer healthcare
  • Health technologies
  • Medical devices
  • Therapeutics